Muscarinic M1 and M4 receptor agonists for schizophrenia: promising candidates for the therapeutic arsenal

IntroductionS: uccessful phase 3 trials of KarXT in people with schizophrenia herald a new era of treating the disorder with drugs that do not target the dopamine D2 receptor. The active component of KarXT is xanomeline, a muscarinic (CHRM) M1 and M4 agonist, making muscarinic receptors a viable target for treating schizophrenia.Areas Covered: This review covers the process of taking drugs that activate the muscarinic M1 and M4 receptors from conceptualization to the clinic and details the mechanisms by which activating the CHRM1 and 4 can affect the broad spectrum of symptoms experienced by people with schizophrenia.Expert Opinion: Schizophrenia is a syndrome which means drugs that activate muscarinic M1 and M4 receptors, as was the case for antipsychotic drugs acting on the dopamine D2 receptor, will not give optimal outcomes in everyone within the syndrome. Thus, it would be ideal to identify people who are responsive to drugs activating the CHRM1 and 4. Given knowledge of the actions of these receptors, it is possible treatment non-response could be restricted to sub-groups within the syndrome who have deficits in cortical CHRM1 or those with one of the cognitive endophenotypes that may be identifiable by changes in the blood transcriptome.

Automated summary

Schizophrenia is a syndrome that requires drugs targeting muscarinic M1 and M4 receptors, rather than dopamine D2 receptors, as antipsychotic drugs do. It would be ideal to identify individuals who respond to drugs activating the CHRM1 and 4 receptors, as non-response to treatment could be restricted to specific sub-groups within the syndrome.